A reduced expression of calcium-sensing receptor (CaR) messenger ribonucleic acid and protein accompanied by abnormalities in parathyroid cell proliferation and PTH secretion are present in primary hyperparathyroidism. We studied the expression of CaR protein by immunohistochemistry in 36 sporadic parathyroid adenomas and investigated the relationship between CaR expression and several preoperative clinical parameters, including the set-point of Ca 2ϩ -regulated PTH secretion (measured in vivo). The adenomas were classified in 4 categories according to the intensity of immunohistochemical staining: 5 (14%) showed a CaR staining intensity similar to that of normal parathyroid (ϩϩϩ), 10 (27%) showed moderate staining (ϩϩ), 16 (45%) showed weak staining (ϩ), and 5 (14%) were negative (Ϫ). The intensity of CaR staining was not related to preoperative serum Ca 2ϩ , PTH levels or adenoma volume. Twenty-nine patients underwent preoperatively the calcium infusion test to evaluate the PTHCa 2ϩ set-point. Individual values of PTH-Ca 2ϩ set-point ranged from 1.38 -1.93 mmol/L and were significantly correlated with basal Ca 2ϩ levels (r ϭ 0.96; P ϭ 0.0001) and adenoma volume (r ϭ 0.5; P ϭ 0.01). The mean PTH-Ca 2ϩ set-point values were significantly different in the 4 groups of patients classified according to immunohistochemical staining intensity of their adenoma (P ϭ 0.025; F ϭ 3.78); the mean PTH-Ca 2ϩ set-point was significantly higher in the groups classified as negative than in those classified as weak or moderate. No correlation was observed between the PTH-Ca 2ϩ set-point and basal PTH levels or between the percent maximal PTH inhibition and adenoma volume and basal PTH or Ca 2ϩ levels. In summary, our data suggest that there is a relationship between apparent CaR protein expression and PTH-Ca 2ϩ set-point abnormality, suggesting that a reduced receptor content might have an important role in the pathogenesis of primary hyperparathyroidism. (J Clin Endocrinol Metab 85: 4789 -4794, 2000) 
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-regulated PTH secretion (measured in vivo). The adenomas were classified in 4 categories according to the intensity of immunohistochemical staining: 5 (14%) showed a CaR staining intensity similar to that of normal parathyroid (ϩϩϩ), 10 (27%) showed moderate staining (ϩϩ), 16 (45%) showed weak staining (ϩ), and 5 (14%) were negative (Ϫ). The intensity of CaR staining was not related to preoperative serum Ca 2ϩ , PTH levels or adenoma volume. Twenty-nine patients underwent preoperatively the calcium infusion test to evaluate the PTHCa 2ϩ set-point. Individual values of PTH-Ca 2ϩ set-point ranged from 1.38 -1.93 mmol/L and were significantly correlated with basal Ca 2ϩ levels (r ϭ 0.96; P ϭ 0.0001) and adenoma volume (r ϭ 0.5; P ϭ 0.01). The mean PTH-Ca 2ϩ set-point values were significantly different in the 4 groups of patients classified according to immunohistochemical staining intensity of their adenoma (P ϭ 0.025; F ϭ 3.78); the mean PTH-Ca 2ϩ set-point was significantly higher in the groups classified as negative than in those classified as weak or moderate. No correlation was observed between the PTH-Ca 2ϩ set-point and basal PTH levels or between the percent maximal PTH inhibition and adenoma volume and basal PTH or Ca 2ϩ levels. In summary, our data suggest that there is a relationship between apparent CaR protein expression and PTH-Ca 2ϩ set-point abnormality, suggesting that a reduced receptor content might have an important role in the pathogenesis of primary hyperparathyroidism. (J Clin Endocrinol Metab 85: 4789 -4794, 2000) P RIMARY HYPERPARATHYROIDISM (PHPT) is characterized by abnormalities in the regulation of parathyroid cell proliferation and PTH secretion (1, 2) . Parathyroid cells in vivo and in vitro respond to increasing concentrations of extracellular ionized calcium (Ca 2ϩ ) with a rapid decrease in PTH secretion (3) (4) (5) (6) (7) (8) . This effect is mediated by a direct interaction of Ca 2ϩ ions with a G protein-coupled, calcium-sensing receptor (CaR) (9, 10) , and the serum Ca 2ϩ concentration half-maximally inhibiting PTH release is defined as the PTH-Ca 2ϩ set-point (1). It is well known that in patients with PHPT a greater concentration of Ca 2ϩ is required to inhibit PTH secretion (2) (3) (4) (5) (6) (7) (8) , but the molecular basis for this abnormality remains to be elucidated. The possibility that alterations in the expression and/or function of the CaR could be involved in this phenomenon has been the subject of active investigation (11, 12) . No mutations in the coding sequence of the CaR gene have been identified in parathyroid tumors (10, 13) , but a reduced messenger ribonucleic acid (mRNA) expression of a CaR promoter has been reported in a recent study (14) . Moreover, a lower expression of CaR mRNA and CaR protein, compared with that in normal parathyroid tissue, has been reported in parathyroid adenomas and hyperplastic glands from patients with uremic hyperparathyroidism (15) (16) (17) .
In the present study we evaluated the expression of CaR protein in a large series of sporadic parathyroid adenomas and investigated the relationship between the level of CaR expression and several clinical parameters, including the set-point of Ca 2ϩ -regulated PTH secretion measured in vivo.
Subjects and Methods Patients
The study group included 36 patients with sporadic PHPT, including 10 men, aged 33-70 yr (mean, 50 yr), and 26 women, aged 27-76 yr (mean, 55.7 yr). The diagnosis of sporadic PHPT was based on elevated Ca 2ϩ (Ͼ1.32 mmol/L) and PTH (Ͼ65 pg/mL) levels and a negative family history.
Twenty-nine patients and 10 normal subjects (8 women and 2 men) participated in the PTH-Ca 2ϩ set-point study. Patients were admitted after an overnight fast to the Department of Endocrinology between 0700 -0900 h. Patients reclined for 30 min to stabilize levels of plasma proteins and calcium, and an iv catheter was placed in each arm, one for blood sampling and the other for calcium infusion. An electrocardiogram was performed before the infusion. After the equilibration period, 5 mL blood were drawn at 60 and 30 min before and immediately before initiating the calcium infusion. The mean Ca 2ϩ and intact PTH concentrations at these time points were considered the basal value for subsequent data analysis. At time zero, calcium gluconate mixed in saline was infused iv for 3 h at a rate of 3 mg elemental calcium/kg⅐h, and blood samples were taken every 30 min for measurement of Ca 2ϩ and intact PTH. The PTH-Ca 2ϩ set-point was defined as the serum Ca 2ϩ concentration corresponding to half-maximal inhibition of basal PTH. The relationship between serum Ca 2ϩ changes and PTH secretion was analyzed using the four-parameter model, as previously described (7) .
Serum ionized calcium was measured using a NOVA 8 calcium analyzer (Nova Biomedical, Waltham, MA). All values were adjusted to pH 7.40 (normal range, 1.13-1.32 mmol/L). Intact PTH was measured using an immunoradiometric assay (Nichols Institute Diagnostics, San Juan Capistrano, CA; normal range, 10 -65 pg/mL).
The decision to recommend parathyroidectomy was based upon the guidelines established by the Consensus Development Conference of the Management of Asymptomatic Primary Hyperparathyroidism (18) .
The local ethical committee approved the study. Both tumor and blood samples were obtained after obtaining informed consent from all patients.
Parathyroid specimens
Pathological parathyroid specimens obtained at the time of surgery were snap-frozen in liquid nitrogen after surgical excision and were stored at Ϫ80 C until analysis. By assuming that the adenoma was ellipsoid, the volume was calculated using the following formula: (x ϫ y ϫ z)x/6, where x, y, and z are the three-dimensional diameters in centimeters. Biopsies of parathyroid glands from two normocalcemic patients operated on for nodular goiter and normal bovine parathyroid glands collected immediately after death were used as control tissues. Histopathological examination by light microscopy was routinely performed on each tissue sample using standard techniques.
Immunohistochemistry
A polyclonal CaR antibody, generated in rabbits with a peptide called FF7 (corresponding to amino acids 345-359 within the predicted extracellular domain of bovine parathyroid CaR) (10, 19) was used. Fivemicron-thick sections of either normal or pathological glands were prepared in a cryostat and stored at 45 Ϫ80 C before use. In each experiment normal gland sections were included as controls, and staining of all normal and abnormal glands was performed simultaneously using the same reagents, the same batch of antiserum, and the identical incubation and washing times, as described below. Frozen sections were air-dried and then fixed for 8 min in acetone at Ϫ20 C, and a minimum of three to five sections were stained and analyzed for each parathyroid specimen, as described below. After treatment for 10 min at room temperature with an inhibitor of endogenous peroxidase (DAKO Corp., Carpinteria, CA), the sections were incubated with a blocking solution (1% BSA and 0.05 sodium azide) for 60 min at room temperature. The slides were then exposed to the CaR antibody for 17-18 h in blocking solution in a humidified chamber at 4 C (20, 21). They were rinsed three times with phosphate-buffered saline (PBS) and incubated with peroxidase-coupled, goat antirabbit secondary antibody for 1 h at room temperature. After washing three times with PBS, peroxidase staining was developed using the DAKO Corp. AEC Substrate System. The slides were subsequently mounted with coverslips and examined by light microscopy. For each sample consecutive sections mounted on the same slide were incubated with the original anti-CaR antibody or with the antibody preabsorbed with the peptide against which it was raised. All adenomas were examined in a single experiment, which was repeated at least three times. Normal human and bovine parathyroid sections, which were used as controls, were included in each experiment.
Each section was evaluated by two independent observers (F.C. and P.C.) at ϫ400 magnification. The presence of a distinct staining along the cell surface of chief cells in a rim-like distribution, which was abolished by preabsorption of the CaR antibody with the specific peptide, was considered specific. The overall intensity of specific staining was scored as negative (Ϫ), weak (ϩ), moderate (ϩϩ), or strong (ϩϩϩ), and the adenomas were grouped in four categories, accordingly; in the case of ϩϩϩ staining, the pattern and intensity of staining were similar to those of control tissues. Samples scored as negative showed irregular and faint staining, which was no different from when the section was incubated with the antibody preabsorbed with the specific peptide. In cases where the assessment of intensity of staining differed between the two observers, the disagreements were resolved by reaching a consensus after joint review using a conference microscope.
Western blot analysis
Tissue specimens were homogenized in ice-cold lysis buffer [50 mmol/L Tris-HCl (pH 7.4); 0.25 mol/L sucrose; 1 mmol/L ethyleneglycol-bis-(B-12-aminoethyl ether)-N,N,NЈ,NЈ-tetraacetic acid and ethylenediamine tetraacetate; 10 g/mL aprotinin, leupeptin, and calpain inhibitor; 40 g/mL bestatin; and 100 g/mL Pefabloc (Roche, Indianapolis, IN)]. Nuclei and cell debris were removed by low speed centrifugation (800 ϫ g). The supernatant was then sedimented at 45,000 ϫ g for 1 h, and the pellet was solubilized with 1% Triton X-100 in 100 L lysis buffer and mixed with 2 ϫ Laemmli sample buffer (22) containing 1 mmol/L dithiothreitol. Proteins (10 g) were separated by SDS-PAGE (22) and transferred to nitrocellulose filters (Schleicher & Schuell, Inc., Keene, NH). After incubation for 1 h with blocking solution (PBS, 0.25% Triton X-100, and 5% dry milk), the filters were incubated in a humidified chamber at 4 C for 15-17 h with the same anti-CaR antibody as that used for immunohistochemistry and were subsequently developed using an enhanced chemiluminescence system (NEN Life Science Products, Boston, MA).
Statistical analysis
All data are expressed as the mean Ϯ sd. ANOVA was used to analyze the statistical differences between several clinical and biochemical parameters in the four groups of adenomas, classified according to the intensity of CaR immunostaining, and significance was assessed by Fisher's test. Simple linear regression was used to analyze the relationship between the PTH-Ca 2ϩ set-point and basal Ca 2ϩ and PTH levels and adenoma volume. An unpaired t test was used to evaluate the difference between PTH-Ca 2ϩ set-point values of PHPT patients and controls. P Ͻ 0.05 was taken to indicate a statistically significant difference.
Results

Patients
The relevant clinical and laboratory data are summarized in Table 1 . Each patient had a single parathyroid adenoma. Preoperative concentrations of serum ionized Ca 2ϩ and intact PTH ranged between 1.32-1.87 mmol/L (mean, 1.49 Ϯ 0.13 mmol/L) and 62-1490 pg/mL (mean, 202 Ϯ 252 pg/ mL), respectively. The volumes of the adenomas ranged from 0.16 -9.82 mL (mean, 1.18 Ϯ 1.66 mL). A linear correlation was found between adenoma volume and baseline PTH (r ϭ 0.87; P ϭ 0.0001) and Ca 2ϩ (r ϭ 0.4; P ϭ 0.008) levels. In 35 cases tumor removal was followed by persistent normalization of serum Ca 2ϩ and PTH concentrations. One patient had recurrence of hyperparathyroidism 1 yr after surgery (no. 6).
Calcium infusion test
Twenty-nine patients underwent the calcium infusion test preoperatively to evaluate the PTH-Ca 2ϩ set-point. During infusion, the serum Ca 2ϩ concentration increased progressively in all patients (mean increase above baseline, 0.2 Ϯ 0.06 mmol/L). The PTH concentration (expressed as a percent decrease compared with the basal value) showed no significant change (Ͻ10%) in 3 cases (no. 11, 28, and 33) despite a marked increase in the serum Ca 2ϩ concentration (from 1.67, 1.53, and 1.69 mmol/L to 1.94, 1.72, and 1.95 mmol/L, respectively). Interestingly, these 3 patients were among those with the highest preoperative Ca 2ϩ and PTH concentrations. A variable degree of inhibition of PTH secretion, ranging from 21-73% (mean, 54 Ϯ 15%), was found in the remaining 26 cases. In these latter cases a successful fit of the corresponding Ca 2ϩ and PTH values was achieved, and the PTH-Ca 2ϩ set-point could be calculated using the 4-parameter model (7) ( Table 1 ). In 10 normal subjects the mean PTH-Ca 2ϩ set-point was 1.23 Ϯ 0.04 mmol/L (range, 1.18 -1.29 mmol/L). In PHPT patients individual PTH-Ca 2ϩ set-points ranged from 1.38 -1.93 mmol/L (mean, 1.53 Ϯ 0.14 mmol/L; P ϭ 0.0001 vs. normal subjects) and were significantly correlated with basal Ca 2ϩ levels (r ϭ 0.96; P ϭ 0.0001) and adenoma volume (r ϭ 0.5; P ϭ 0.01). On the other hand, no correlation was observed between the PTH-Ca 2ϩ set-point and basal PTH levels or between the percent maximal PTH inhibition and adenoma volume and basal PTH or Ca 2ϩ levels.
Immunohistochemistry
The normal parathyroid tissue showed an intense and specific staining along the cell surface in a rim-like distribution (Fig. 1A) and was scored as ϩϩϩ. In all but 5 (14%) parathyroid adenomas, which were similar to normal parathyroid tissue in the intensity of their CaR immunoreactivity and were scored, therefore, as ϩϩϩ, the intensity of staining was decreased in a uniform pattern throughout the gland: ϩϩ in 10 (27%) cases, ϩ in 16 (45%) cases, and Ϫ in 5 (14%) cases (Fig. 1, B and C) . The specificity of the staining was confirmed in each case by abolition of the staining after preabsorption of the anti-CaR antibody with the specific peptide against which it was raised (Fig. 1D) .
To validate the immunohistochemical scoring method, expression of the CaR protein was also analyzed in a subset (n ϭ 6) of parathyroid adenomas using Western blotting. Two major bands of 120 -150 kDa, corresponding to the intact glycosylated receptor, were identified in control tissue (normal human parathyroid glands), and their intensities were variably reduced in membranes prepared from pathological glands (Fig. 2) . These two bands were absent when peptidepreabsorbed antiserum was used for blotting (data not shown). The fainter bands with lower molecular weights present in most adenoma samples, but not in normal parathyroid, most likely represent degradation products of the CaR and partially disappeared when preabsorbed CaR antibody was used. As indicated in Fig. 2 , there was a good correlation between the intensity of CaR immunoreactive bands on Western blotting and the immunohistochemical scoring of individual samples.
Relationship between CaR expression and clinical and biochemical parameters
The relationship between CaR expression and several clinical and biochemical parameters is summarized in Table 2 . ANOVA showed a statistically significant difference between the mean PTH-Ca 2ϩ set-point values (in the 26 cases in whom it could be estimated) in the 4 groups of adenomas classified according to the intensity of immunostaining (P ϭ 0.025; F ϭ 3.78). In particular, the mean PTH-Ca 2ϩ set-point was significantly higher in the group of patients whose parathyroid adenoma was classified as negative at immunohistochemistry than in those classified as weak or moderate. In contrast, there was no difference in the 4 groups in preoperative serum Ca 2ϩ , PTH levels, or adenoma volume, even though the Ca 2ϩ concentration and adenoma volume tended to be higher in patients with absent or marked decreases in CaR expression compared with the other groups. Interestingly, CaR expression was markedly reduced in the 3 patients with nonsuppressible PTH during calcium infusion (no. 11, 28, and 33). 
Discussion
Abnormal regulation of PTH secretion by Ca 2ϩ plays an important role in the pathophysiology of hypercalcemia in PHPT. In vitro studies have shown that adenomatous parathyroid cells secrete more PTH at any given level of Ca 2ϩ and are set to maintain the serum Ca 2ϩ concentration at a constant, but higher, level than normal (1-6). To explain this finding, Parfitt and co-workers suggested that pathological parathyroid cells continue to proliferate until the size of the adenoma is such that the amount of PTH secreted is sufficient to increase serum Ca 2ϩ to the level corresponding to a given pathological parathyroid gland's set-point, and therefore a steady state is reached (23) . These concepts are in keeping with the in vivo observation that patients with PHPT have a higher PTH-Ca 2ϩ set-point than normal subjects (1-7). The recent cloning of the CaR (9, 10) has greatly clarified the mechanism by which parathyroid cells sense extracellular Ca 2ϩ , and alterations in the receptor's structure and/or level of expression have been actively sought as possible explanations for the above-noted abnormalities in Ca 2ϩ -regulated PTH release in patients with HPTH (11) (12) (13) . To date, in sporadic parathyroid adenomas no mutations in the CaR gene have been reported (11, 13) . A recent study has shown a reduced level of expression of the mRNA for a CaR promoter (14) , but the question of whether a mutation in the noncoding region of the CaR gene is the basis for this abnormality remains to be determined. Reduced levels of expression of otherwise apparently normal CaR mRNA and protein have been reported in pathological parathyroid glands from patients with PHPT in several studies (15) (16) (17) . As expected, in our series there was also a variable decrease in CaR protein expression as assessed by immunohistochemistry in parathyroid tumors compared with normal parathyroid glands from normocalcemic subjects. Western blot analysis of membrane proteins isolated from normal and pathological parathyroid glands using the same CaR antibody shows that most of the protein labeled had a molecular mass compatible with that of the glycosylated CaR protein (M r ϭ 130 -150). The fainter bands with lower molecular masses present in most parathyroid adenomas, but not in normal parathyroid, have been observed in other studies (15, 24) and were only partially abolished when preabsorbed CaR antibody was used. They may represent partially degraded CaR or nonspecific staining. The intensity of staining was not correlated with the basal levels of Ca 2ϩ or PTH levels or with adenoma volume. In our series five parathyroid adenomas were scored as negative for CaR expression. This finding is at variance with the results of other studies that also used immunohistochemistry (15, 16) and may be related to difference in the method used to quantify protein expression. It should be pointed out, however, that in three of these cases, PTH levels in vivo were essentially nonsuppressible during calcium infusion, which would be consistent with the markedly abnormal levels of CaR expression in these glands. In any case, the question of whether the reduced expression of the CaR protein represents a primary or a secondary phenomenon is still a matter for discussion.
It is well known that in patients with PHPT there is an increase in the set-point of Ca 2ϩ -regulated PTH secretion, and it has been suggested that a reduction in CaR protein might account for this abnormality. Indeed, in vitro studies have shown that there is a correlation between the progressive loss of suppression of PTH secretion and a reduction of CaR mRNA and protein expression in bovine parathyroid cells in culture (19) . Moreover, a relationship between setpoint and number of abnormal CaR alleles has been reported in familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism (5, 25) .
To address this issue we evaluated in vivo PTH secretion during calcium infusion and compared the results with the CaR protein expression in the parathyroid adenoma surgically resected from the same patient. Most of our patients showed an increase in the PTH-Ca 2ϩ set-point compared with what has been reported in normal subjects (26) , and baseline serum Ca 2ϩ was the strongest predictor of this change. Moreover, there was a statistically significant difference between the mean PTH-Ca 2ϩ set-point in the four groups of patients ranked according to the intensity of CaR immunostaining of the parathyroid adenoma. In particular, the mean PTH-Ca 2ϩ set-point was higher in the group of patients with negative CaR staining, suggesting that the apparent lack of expression of CaR is associated with a more severe abnormality in the control of Ca 2ϩ -regulated PTH release. Finally, a significant correlation was observed between the PTH-Ca 2ϩ set-point and adenoma volume, indicating that parathyroid hyperplasia may also play a role in Results are expressed as the mean Ϯ SD. a CaR expression was scored as negative (Ϫ), weak (ϩ), moderate (ϩϩ), or strong (ϩϩϩ); in the latter case, the pattern of staining was similar to that in control tissues.
b Volume was calculated assuming that the adenoma was ellipsoid (see Subjects and Methods). c The number in parentheses indicates the patients in whom the PTH-Ca ϩ set-point was measured. d ND, Not determined. e P Ͻ 0.001 vs. each group of adenomas classified according to the intensity of CaR immunostaining (by ANOVA and Fisher test).
the abnormality of PTH secretion in PHPT. This pathogenic mechanism may be particularly relevant in the group of adenomas with CaR staining (ϩϩϩ) similar to that of normal parathyroid.
In summary, the results of the present study are consistent with previous data showing a substantial reduction of CaR expression in parathyroid adenomas from patients with sporadic PHPT. Our data also suggest that there is a relationship between the apparent CaR protein expression and PTH-Ca 2ϩ set-point abnormality, suggesting that a reduced receptor content might have an important role in the pathogenesis of PHPT.
